艾司西酞普兰与帕罗西汀治疗老年抑郁症患者的临床效果比较

Comparison of the Clinical Effect of Escitalopram and Paroxetine in the Treatment of Elderly Patients with Depression

目的探讨艾司西酞普兰与帕罗西汀在老年抑郁症中的应用效果。方法选取2020年3月—2023年10月我院收治的64例老年抑郁症患者为研究对象,按随机数字表法将其分为对照组与观察组,各32例。对照组采用帕罗西汀治疗,观察组采用艾司西酞普兰治疗,持续治疗12周。比较两组临床疗效、汉密尔顿抑郁量表(HAMD)评分、匹兹堡睡眠质量指数(PSQI)评分、脑神经因子、生活质量及不良反应发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组HAMD评分、PSQI评分分别为(13.58±1.38)分、(5.34±1.03)分,均低于对照组的(16.82±1.54)分、(7.67±1.12)分,组间差异有统计学意义(P<0.05);观察组5-羟色胺、脑源性神经营养因子水平分别为(290.29±25.47)μg/L、(28.74±2.65)ng/L,均高于对照组的(265.74±24.18)μg/L、(23.85±2.57)ng/L,神经元特异性烯醇化酶水平为(5.89±1.05)ng/mL,低于对照组的(7.75±1.12)ng/mL,组间差异有统计学意义(P<0.05);观察组生活质量评分分别为(86.57±5.24)分、(87.41±5.32)分、(88.74±5.34)分、(90.41±4.35)分,均高于对照组的(79.63±5.19)分、(80.57±5.28)分、(82.04±5.29)分、(83.14±4.82)分,组间差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论在老年抑郁症治疗中艾司西酞普兰效果更佳,可加快抑郁情绪消失,减轻患者睡眠障碍,降低疾病对生活的影响,安全可靠。

Objective To investigate the effect of escitalopram and paroxetine in the treatment of senile depression.Methods A total of 64 elderly patients with depression admitted to our hospital from March 2020 to October 2023 were selected as the research objects,and they were divided into a control group and an observation group according to the random number table method,with 32 cases in each group.The control group was treated with paroxetine,and the observation group was treated with escitalopram for 12 weeks.The clinical efficacy,Hamilton Depression Scale(HAMD)score,Pittsburgh Sleep Quality Index(PSQI)score,brain nerve factors,quality of life and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the HAMD score and PSQI score of the observation group were(13.58±1.38)points and(5.34±1.03)points,respectively,which were lower than(16.82±1.54)points and(7.67±1.12)points of the control group,the differences were statistically significant(P<0.05);the levels of serotonin and brain-derived neurotrophic factor in the observation group were(290.29±25.47)μg/L and(28.74±2.65)ng/L,respectively,which were higher than(265.74±24.18)μg/L and(23.85±2.57)ng/L in the control group,the level of neuron-specific enolase was(5.89±1.05)ng/mL,which was lower than(7.75±1.12)ng/mL in the control group,the differences between the two groups were statistically significant(P<0.05);the The World Health Organization Quality of Life-BREF scores of the observation group were(86.57±5.24)points,(87.41±5.32)points,(88.74±5.34)points and(90.41±4.35)points,respectively,the scores were higher than(79.63±5.19)points,(80.57±5.28)points,(82.04±5.29)points,(83.14±4.82)points of the control group,the differences between the two groups were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Escitalopram is more effective in the treatment of senile depression,which can speed up the disappearance of depression,reduce sleep disorders,reduce the impact of disease on life,and is safe and reliable.